Point: Major adverse cardiovascular events and anti-IL 12/23 agents - 16/01/14
Doi : 10.1016/j.jaad.2013.07.050
Thrasivoulos Tzellos, MD a, b, Athanassios Kyrgidis, MD a, b, Anastasia Trigoni, MD c, Christos C. Zouboulis, MD b, ⁎ 
a Department of Pharmacology and Clinical Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Greece
b Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
c Hospital for Skin and Venereal Diseases, Thessaloniki, Greece
∗Correspondence to: Christos C. Zouboulis, MD, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Auenweg 38, 06847 Dessau, Germany
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Tzellos has been reimbursed for travel expenses and hotel accommodation to attend dermatological congresses by Janssen-Cilag, which produces ustekinumab (Stelara), by MSD, which produces infliximab (Remicade), and by Novartis. Dr Zouboulis has been reimbursed for travel expenses and hotel accommodation and has received honorarium for participating and lecturing at the Advisory Board for hidradenitis suppurativa of AbbVie, which produces adalimumab (Humira). He has also participated and continues to participate at clinical studies on the treatment of hidradenitis suppurativa with adalimumab sponsored by AbbVie. Dr Trigoni has participated at clinical trials for chronic plaque psoriasis sponsored by Abbott, Janssen-Cilag, Pfizer, and MSD. Dr Kyrgidis declares no conflict of interest. |
© 2013
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 70 - N° 2
P. 380-381 - février 2014 Retour au numéro
Article précédent
- Keep on “Liking” us: The JAAD’s Facebook page turns 2 years old
- Chante Karimkhani, Ryan Gamble, Robert P. Dellavalle
- Counterpoint: A tale of two meta-analyses revisited
- Erica D. Dommasch, Andrea B. Troxel, Joel M. Gelfand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?